Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Will US Supreme Court Come To Teva’s Rescue On ‘Skinny Label’ Battle?

Israeli Firm Petitions For Certiorari Review Of Labelling Carve-Outs Litigation With GSK

Executive Summary

Teva has made good on its stated intention to bring its long-running US legal battle with GSK over “skinny-label” generics to the Supreme Court. In a detailed certiorari petition, the firm sets out its arguments for why the matter warrants review.

You may also be interested in...

Stage Set For Generics To Triumph With Skinny-Label Reversal

With the US solicitor general offering support for Teva over GSK in long-running litigation over skinny-label carve-outs of generic indications, the stage could be set for a major reversal at the Supreme Court that would favor the generics industry.

Skinny-Label Saga Hangs In Balance As Supreme Court Seeks Input

As the US Supreme Court deliberates on whether to grant Teva’s petition to review its litigation with GSK over “skinny label” generics that carve out patented indications, Aziz Burgy, partner at Axinn, Veltrop & Harkrider LLP, talks to Generics Bulletin about the key issues at stake.

Teva Plans To Take Skinny-Label Defeat To Supreme Court

Following the decision by the US Court of Appeals for the Federal Circuit not to rehear “en banc” Teva’s litigation with GSK revolving around skinny-label generic carvedilol, the Israeli company has confirmed that it will seek Supreme Court review of the ruling.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts